Related Experiment Videos
Comparative studies between liposomes containing muramyl dipeptide and various immunomodulators on activation of
Abstract:
We compared the effects among muramyl dipeptide (MDP), liposome-encapsulated MDP (liposome MDP), bacillus Calmette-Guérin (BCG) and OK-432 on cytotoxic activity of mouse peritoneal macrophages (PM) and natural killer (NK) cells in vitro and in vivo, and their tumor-inhibitory effects against MH134 ascitic tumors in C3H/He mice. The cytotoxicity of PM induced by free MDP was lower than that induced by BCG, but a significantly higher cytotoxicity was induced by liposomes containing MDP and OK-432. The peritoneal NK cells were not activated by MDP, liposome MDP or BCG, but OK-432 profoundly augmented peritoneal NK activity. Growth inhibition of ascitic tumor was not observed in free MDP and BCG intraperitoneally treated mice, but moderate growth inhibition was noted in liposome-MDP-treated mice; and in OK-432-treated mice, marked tumor growth inhibition and prolongation of survival time were observed. These results suggested that OK-432 is more advantageous in controlling malignant tumor growth in vivo than free MDP, liposome MDP or BCG because of its ability to activate both macrophages and NK cells.
Insights
OK-432 demonstrated superior tumor inhibition compared to muramyl dipeptide (MDP) and bacillus Calmette-Guérin (BCG) in mice. This immunotherapy activates both macrophages and natural killer (NK) cells, leading to significant tumor growth control.
Area of Science:
- Immunology
- Cancer Research
- Pharmacology
Background:
- Muramyl dipeptide (MDP), bacillus Calmette-Guérin (BCG), and OK-432 are known immunomodulators.
- Assessing their comparative efficacy in activating immune cells and inhibiting tumor growth is crucial for therapeutic development.
Purpose of the Study:
- To compare the in vitro and in vivo effects of MDP, liposome-encapsulated MDP, BCG, and OK-432.
- To evaluate their impact on cytotoxic activity of mouse peritoneal macrophages (PM) and natural killer (NK) cells.
- To determine their tumor-inhibitory effects against MH134 ascitic tumors.
Main Methods:
- In vitro and in vivo experiments were conducted using C3H/He mice.
- Cytotoxic activity of peritoneal macrophages (PM) and natural killer (NK) cells was measured.
- Tumor-inhibitory effects were assessed against MH134 ascitic tumors.
Main Results:
- Liposome MDP and OK-432 induced significantly higher PM cytotoxicity than free MDP or BCG.
- OK-432 profoundly augmented peritoneal NK cell activity, while other agents did not.
- OK-432 treatment resulted in marked tumor growth inhibition and prolonged survival, unlike free MDP and BCG.
Conclusions:
- OK-432 is more advantageous in controlling malignant tumor growth in vivo than free MDP, liposome MDP, or BCG.
- OK-432's efficacy stems from its ability to activate both macrophages and NK cells.
- These findings highlight OK-432 as a promising immunotherapeutic agent for cancer treatment.